These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Proximal renal tubular function in HIV-infected children on tenofovir disoproxil fumarate for treatment of HIV infection at two tertiary hospitals in Harare, Zimbabwe. Mashingaidze-Mano R, Bwakura-Dangarembizi MF, Maponga CC, Morse GD, Monera-Penduka TG, Mtisi TJ, Mudzviti T, Mujuru HA. PLoS One; 2020; 15(7):e0235759. PubMed ID: 32634168 [Abstract] [Full Text] [Related]
3. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons. Adedeji TA, Adebisi SA, Adedeji NO. Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318 [Abstract] [Full Text] [Related]
4. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression. Huang WC, Huang CK, Huang SH, Lin SW, Ou ST, Chen YT, Chen YW, Chang SY, Liu WC, Sun HY, Hung CC. J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042 [Abstract] [Full Text] [Related]
5. Effects of Prolonged Administration of Tenofovir Disoproxil Fumarate-Containing Antiviral Regimen on Renal Function in Low-Risk of Kidney Injury HIV Patients. Yuan Y, He S, Liu H, He Y, Zhou R, Yao Y, Yin K, Lyu C. J Clin Pharmacol; 2024 May; 64(5):626-633. PubMed ID: 38323669 [Abstract] [Full Text] [Related]
7. Prevalence and predictors of long-term progression of chronic kidney disease in people with HIV in Ghana from 2003-2018. Chadwick DR, Barker F, Smith C, Perditer O, Hardy Y, Owusu D, Villa G, Sarfo FS, Geretti AM, Phillips R. BMC Nephrol; 2024 Jul 29; 25(1):241. PubMed ID: 39075393 [Abstract] [Full Text] [Related]
14. The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis. Salome T, Kasamba I, Mayanja BN, Kazooba P, Were J, Kaleebu P, Munderi P, CoLTART study team. AIDS Res Ther; 2016 Jul 29; 13(1):28. PubMed ID: 27582777 [Abstract] [Full Text] [Related]
15. COMPARISON OF THAI GOVERNMENT MANUFACTURED TENOFOVIR (TENOFOVIR GPO300) WITH PRIVATELY MANUFACTURED TENOFOVIR (VIREAD) USED ALONG WITH LAMIVUDINE AND EFAVIRENZ TO TREAT THAI HIV PATIENTS. Manosuthi W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S. Southeast Asian J Trop Med Public Health; 2015 Jan 29; 46(1):19-26. PubMed ID: 26513901 [Abstract] [Full Text] [Related]
18. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. Gallant JE, Winston JA, DeJesus E, Pozniak AL, Chen SS, Cheng AK, Enejosa JV. AIDS; 2008 Oct 18; 22(16):2155-63. PubMed ID: 18832879 [Abstract] [Full Text] [Related]
20. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir. Gianotti N, Galli L, Poli A, Salpietro S, Nozza S, Carbone A, Merli M, Ripa M, Lazzarin A, Castagna A. Medicine (Baltimore); 2016 May 18; 95(22):e3780. PubMed ID: 27258510 [Abstract] [Full Text] [Related] Page: [Next] [New Search]